ArticleCancer causes & control : CCC2025
Utilization of cancer-directed surgical therapy in Medicaid patients with cancer: comparison between low/intermediate/high-risk surgeries.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt is unknown whether underutilization of cancer-directed surgery (CDS) in patients with Medicaid contributes to worse overall survival (OS) across various operative risk spectrum in comparison to non-Medicaid patients.
methodThe SEER database linked to Medicaid enrollment files between 2006 and 2013 was used. Spectrum of operative risks included pancreatic ductal adenocarcinoma (PDAC)-high-risk, colon cancer (CC)-intermediate-risk, or melanoma-low-risk. Multivariable Cox proportional-hazard and logistic regression analyses were used.
resultsThere were 7,595 Medicaid and 163,416 non-Medicaid patients. Being in Medicaid was associated with higher odds of not undergoing CDS for CC (OR 1.88, 95% CI 1.41-2.52) and PDAC (OR 2.20, 95% CI 1.73-2.80). Correspondingly, not undergoing CDS was associated with worse survival (CC-HR 4.76, 95% CI 3.82-5.93; PDAC-HR 2.40, 95% CI 2.21-2.60) in Medicaid group vs non-Medicaid group. For melanoma, there was a larger impact of not undergoing CDS on OS in Medicaid compared to non-Medicaid population (HR 1.75, 95% CI 1.07-2.89).
conclusionAcross cancers with different operative risks, increasing the use of CDS may help reduce the OS gaps between Medicaid and non-Medicaid population.
Indexed as
Identifiers
40402388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.